Gladius Capital Management LP Makes New $30,000 Investment in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Gladius Capital Management LP acquired a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the 4th quarter, Holdings Channel reports. The firm acquired 4,605 shares of the company’s stock, valued at approximately $30,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in MRVI. Performa Ltd US LLC lifted its position in shares of Maravai LifeSciences by 112.4% during the 4th quarter. Performa Ltd US LLC now owns 6,000 shares of the company’s stock worth $39,000 after buying an additional 3,175 shares in the last quarter. National Bank of Canada FI increased its holdings in Maravai LifeSciences by 509,962.5% during the 4th quarter. National Bank of Canada FI now owns 204,025 shares of the company’s stock worth $1,375,000 after acquiring an additional 203,985 shares during the period. M&T Bank Corp boosted its holdings in Maravai LifeSciences by 17.3% in the 4th quarter. M&T Bank Corp now owns 20,107 shares of the company’s stock valued at $131,000 after purchasing an additional 2,972 shares during the period. Victory Capital Management Inc. grew its position in Maravai LifeSciences by 237.4% during the fourth quarter. Victory Capital Management Inc. now owns 110,468 shares of the company’s stock worth $724,000 after buying an additional 77,727 shares in the last quarter. Finally, Sivik Global Healthcare LLC purchased a new stake in Maravai LifeSciences in the fourth quarter valued at approximately $1,344,000. Institutional investors own 50.25% of the company’s stock.

Analyst Upgrades and Downgrades

MRVI has been the topic of a number of analyst reports. Robert W. Baird lifted their price target on Maravai LifeSciences from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday. Royal Bank of Canada upped their price objective on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, February 23rd. Stifel Nicolaus reduced their price target on Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, February 23rd. Finally, Craig Hallum initiated coverage on Maravai LifeSciences in a report on Wednesday, April 10th. They issued a “buy” rating and a $15.00 price objective for the company. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.44.

Maravai LifeSciences Stock Up 11.2 %

Shares of NASDAQ:MRVI traded up $0.99 during midday trading on Thursday, reaching $9.86. The company’s stock had a trading volume of 5,157,152 shares, compared to its average volume of 2,509,449. Maravai LifeSciences Holdings, Inc. has a 12-month low of $4.52 and a 12-month high of $16.62. The company has a quick ratio of 7.41, a current ratio of 8.00 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average of $8.09 and a 200-day moving average of $6.73. The firm has a market capitalization of $2.48 billion, a P/E ratio of -10.47 and a beta of 0.03.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Thursday, February 22nd. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The business had revenue of $74.14 million for the quarter, compared to the consensus estimate of $62.99 million. Maravai LifeSciences had a negative net margin of 41.19% and a negative return on equity of 1.31%. On average, research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.15 earnings per share for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.